Published in Scanning Microsc on January 01, 1996
Nephropathy in dietary hyperoxaluria: A potentially preventable acute or chronic kidney disease. World J Nephrol (2014) 0.87
Limitation of apoptotic changes in renal tubular cell injury induced by hyperoxaluria. Urol Res (2004) 0.81
Antiapoptotic effect of angiotensin-II type-1 receptor blockade in renal tubular cells of hyperoxaluric rats. Urol Res (2010) 0.75
Morphometric analysis of Bruch's membrane, the choriocapillaris, and the choroid in aging. Invest Ophthalmol Vis Sci (1994) 3.37
Microscopic haematuria. BMJ (1994) 3.00
Prostate cancer: to screen or not to screen? BMJ (1993) 2.41
Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol (2001) 2.33
Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol (2007) 2.26
Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol (1994) 1.94
Late degradation tissue response to poly(L-lactide) bone plates and screws. Biomaterials (1995) 1.84
In vivo degradation and biocompatibility study of in vitro pre-degraded as-polymerized polyactide particles. Biomaterials (1995) 1.69
The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J Urol (1997) 1.67
Adrenal glands of mouse and rat do not synthesize androgens. Life Sci (1992) 1.64
Pathologic features of prostate cancer found at population-based screening with a four-year interval. J Natl Cancer Inst (2001) 1.63
Is basal laminar deposit unique for age-related macular degeneration? Arch Ophthalmol (1991) 1.61
Foreign body reactions to resorbable poly(L-lactide) bone plates and screws used for the fixation of unstable zygomatic fractures. J Oral Maxillofac Surg (1993) 1.60
Cutaneous metastasis following laparoscopic pelvic lymphadenectomy for prostatic carcinoma. J Urol (1995) 1.59
Future prospects in prostate cancer. Prostate (1999) 1.53
Anxiety and depression after prostate cancer diagnosis and treatment: 5-year follow-up. Br J Cancer (2006) 1.51
Screening for prostate cancer--more questions than answers. Acta Oncol (1998) 1.40
Errors in transrectal ultrasonic planimetry of the prostate: computer simulation of volumetric errors applied to a screening population. Ultrasound Med Biol (1995) 1.39
Treatment of benign prostatic hyperplasia by transurethral ultrasound-guided laser-induced prostatectomy (TULIP): effects on urodynamic parameters and symptoms. Urology (1994) 1.39
Histologic features of the early stages of age-related macular degeneration. A statistical analysis. Ophthalmology (1992) 1.37
[Diagnosis based on prostate needle biopsy: inadequate correlation between pathologic results and clinical course for individual prognosis]. Ned Tijdschr Geneeskd (2005) 1.37
Short-term effects of population-based screening for prostate cancer on health-related quality of life. J Natl Cancer Inst (1998) 1.36
European Randomized Study of Screening for Prostate Cancer: achievements and presentation. BJU Int (2003) 1.32
Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands). BJU Int (2003) 1.30
Detection of prostate cancer. BMJ (1995) 1.30
Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am J Pathol (1996) 1.29
Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM). Urology (2004) 1.25
Modalities available for screening for prostate cancer. Eur J Cancer (1993) 1.23
Idiopathic infantile arterial calcification in siblings: radiologic diagnosis and successful treatment. J Pediatr (1978) 1.22
Calcium oxalate nephrolithiasis: effect of renal crystal deposition on the cellular composition of the renal interstitium. Am J Kidney Dis (1999) 1.20
Early stages of age-related macular degeneration: an immunofluorescence and electron microscopy study. Br J Ophthalmol (1993) 1.19
Identification of genetic markers for prostatic cancer progression. Lab Invest (2000) 1.19
Glycogen, its chemistry and morphologic appearance in the electron microscope. I. A modified OsO 4 fixative which selectively contrasts glycogen. J Ultrastruct Res (1973) 1.16
A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands. Br J Cancer (2010) 1.16
Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins. Eur J Cancer (1999) 1.16
Coats's disease: definition and pathogenesis. Br J Ophthalmol (1967) 1.16
Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community. Urology (1995) 1.15
Migration of dendritic cells into the draining lymph nodes of the lung after intratracheal instillation. Am J Respir Cell Mol Biol (1993) 1.15
Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer. Urology (2005) 1.11
Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features. Am J Pathol (2001) 1.11
Why do men refuse or attend population-based screening for prostate cancer? J Public Health Med (2000) 1.11
Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol (1998) 1.10
Immunohistochemical light and electron microscopy of basal laminar deposit. Graefes Arch Clin Exp Ophthalmol (1994) 1.09
Positive margins after radical prostatectomy: correlation with local recurrence and distant progression. Br J Urol (1993) 1.08
Orthotopic implantation of human prostate cancer cell lines: a clinically relevant animal model for metastatic prostate cancer. Prostate (1997) 1.07
Prospective evaluation plan for randomised trials of prostate cancer screening. The International Prostate Cancer Screening Trial Evaluation Group. J Med Screen (1996) 1.06
Hormonal manipulation of prostatic cancer. BMJ (1991) 1.06
Increased prevalence of disciform macular degeneration after cataract extraction with implantation of an intraocular lens. Br J Ophthalmol (1994) 1.06
Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. J Urol (2000) 1.05
Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol (2007) 1.05
Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group. Eur Urol (1999) 1.04
Quebec randomized controlled trial on prostate cancer screening shows no evidence for mortality reduction. Prostate (1999) 1.04
Increased calcium oxalate monohydrate crystal binding to injured renal tubular epithelial cells in culture. Am J Physiol (1998) 1.04
Effects of extracorporeal shock wave lithotripsy (ESWL) on renal tissue. A review. Urol Res (1989) 1.04
Reasons for the weak correlation between prostate volume and urethral resistance parameters in patients with prostatism. J Urol (1995) 1.03
Role of macrophages in nephrolithiasis in rats: an analysis of the renal interstitium. Am J Kidney Dis (2000) 1.02
Association of calcium oxalate monohydrate crystals with MDCK cells. Kidney Int (1995) 1.01
Tissue specific and androgen-regulated expression of human prostate-specific transglutaminase. Biochem J (1996) 1.01
Screening for prostate cancer. Eur J Cancer (2005) 1.01
Management of benign prostatic hyperplasia with particular emphasis on aromatase inhibitors. J Steroid Biochem Mol Biol (1993) 1.00
Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. World J Urol (2011) 1.00
Repeat screening for prostate cancer after 1-year followup in 984 biopsied men: clinical and pathological features of detected cancer. J Urol (1998) 0.99
Effects of low testosterone levels and of adrenal androgens on growth of prostate tumor models in nude mice. J Steroid Biochem Mol Biol (1990) 0.98
The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer. BJU Int (2004) 0.98
Long-term effects of buserelin on plasma testosterone and luteinising hormone concentrations. Lancet (1985) 0.97
The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer. Prostate (2008) 0.97
Value of tissue markers p27(kip1), MIB-1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer. J Pathol (2002) 0.97
Castration-induced changes in morphology, androgen levels, and proliferative activity of human prostate cancer tissue grown in athymic nude mice. Prostate (1993) 0.97
Parameters of prostate volume and shape in a community based population of men 55 to 74 years old. J Urol (1994) 0.96
Serendipity in detecting disease in low prostate-specific antigen ranges. BJU Int (2002) 0.96
Do neuroendocrine cells in human prostate cancer express androgen receptor? Histochemistry (1993) 0.96
Separation of alveolar macrophages and dendritic cells via autofluorescence: phenotypical and functional characterization. J Leukoc Biol (1993) 0.96
The human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model for the study of androgen sensitivity. J Steroid Biochem Mol Biol (1991) 0.96
Low all-cause mortality in the volunteer-based Rotterdam section of the European randomised study of screening for prostate cancer: self-selection bias? J Med Screen (2004) 0.95
Evaluation of prostate needle biopsies in a population-based screening study: the impact of borderline lesions. Cancer (1999) 0.95
Atrophy in prostate needle biopsy cores and its relationship to prostate cancer incidence in screened men. Urology (2005) 0.95
PSA screening for prostate cancer: the current controversy. Ann Oncol (1998) 0.94
Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer. J Urol (2001) 0.94
Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml). Prostate (2001) 0.94
An ultrastructural study of experimentally induced microliths in rat proximal and distal tubules. J Urol (1993) 0.94
The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. Clin Cancer Res (1997) 0.94
Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation. Cancer Res (2000) 0.94
Oxalate toxicity in renal epithelial cells: characteristics of apoptosis and necrosis. Toxicol Appl Pharmacol (2000) 0.93
Extracorporeal shockwave lithotripsy of gallstones. Possibilities and limitations. Ann Surg (1989) 0.93
Biocompatibility study of as-polymerized poly(L-lactide) in rats using a cage implant system. J Biomed Mater Res (1995) 0.92
Treatment of local-regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors. Br J Cancer (2013) 0.92
Neuroendocrine differentiation in human prostatic tumor models. Am J Pathol (1996) 0.92
Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone. Lab Invest (1997) 0.92
A note on the composition and properties of ferritin iron cores. J Inorg Biochem (1987) 0.92
Cytokine production induced by binding and processing of calcium oxalate crystals in cultured macrophages. Am J Kidney Dis (2001) 0.91